Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma
Conditions
Brief summary
This is a two-arm, open, multicenter clinical study to evaluate the efficacy and safety of AK104 alone or in combination with cisplatin and paclitaxel in the treatment of advanced esophageal squamous carcinoma without systemic therapy.
Detailed description
During the treatment, eligible patients in cohort A with PD-L1 CPS ≥5 will receive AK104 10 mg/kg, intravenously, every 3 weeks (maximum 24 months of dosing); in cohort B, regardless of PD-L1 expression, eligible patients will receive AK104 10 mg/kg, intravenously, every 3 weeks (maximum 24 months of dosing), in combination with cisplatin (75 mg/m2) and paclitaxel (175 mg/m2), Q3W (up to 6 cycles, the specific cycles will be determined by the investigator). Thereafter, AK104 maintenance therapy will be continued until disease progression, intolerable toxicity, withdrawal of informed consent, death, or end of the study, whichever occurred first (maximum duration of treatment with AK104 should be less than 12 months). When patients with initially unresectable disease transformed into resectable, an operation can be considered and the original regimen may be used after surgery.
Interventions
DRUGAK104
10mg/kg IV every 3 weeks (Q3W)
DRUGCisplatin
75mg/m2 IV every 3 weeks (Q3W)
DRUGPaclitaxel
175mg/m2 IV every 3 weeks (Q3W)
Sponsors
Akeso Pharmaceuticals, Inc.
Chinese Academy of Medical Sciences
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age: 18 to 75 years old, men or women are not limited 2. Histologically or cytologically confirmed as esophageal squamous cell carcinoma (including the gastroesophageal junction), (adenosquamous carcinoma with a predominantly squamous component is allowed) 3. Unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma 4. Patients who have never received systemic antitumor therapy 5. ECOG score 0-1 6. Patients who have measurable lesions that meet RECIST 1.1 criteria 7. Patients who are expected to survive more than 3 months 8. Women of childbearing age must have a negative pregnancy test (serum or urine) and voluntarily use an appropriate method of contraception 9. Patients who are voluntarily enrolled in the study and sign an informed consent form (ICF) 10. Patients who are well adherent and able to follow up the study protocol 11. Patients with normal function organs, no serious abnormalities of blood, heart, lung, liver, kidney function, and immunodeficiency diseases. 12. Patients with normal coagulation function, no active bleeding, and thrombotic disease 13. cohort A: AK104 monotherapy cohort enrolling patients with esophageal cancer tumor tissue PD-L1 CPS ≥ 5 (uniformly using Dako 22C3 antibody)
Exclusion criteria
1. Locally advanced esophageal cancer that can be radically resectable or potentially cured by radiotherapy 2. Other malignancies diagnosed within 5 years prior to the first administration of the study drug, except effectively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or effectively resected in situ cervical and/or breast cancer 3. Symptomatic central nervous system metastases (brain metastases confirmed stable by imaging for more than 3 months can be enrolled) 4. A serious infection (CTCAE \> grade 2) such as severe pneumonia requiring hospitalization, bacteremia, or infectious comorbidities that occurred within 4 weeks prior to the first administration of the study drug; baseline chest imaging suggestive of active pulmonary inflammation with clinically relevant signs or symptoms; signs and symptoms of infection within 2 weeks prior to the first administration of study drug, or requiring oral, or intravenous antibiotic therapy. Excluding prophylactic use of antibiotics 5. Patients with previous and current interstitial pneumonia, pneumoconiosis, drug-related pneumonia, or severely impaired lung function that may interfere with the detection and management of suspected drug-related pulmonary toxicity; patients with radiation pneumonia within 6 months 6. Patients with active tuberculosis infection detected by history or CT examination, patients with a history of active tuberculosis infection within 1 year prior to enrollment, or patients with a history of active tuberculosis infection more than 1 year ago but without formal treatment 7. Patients previously treated with immune checkpoint inhibitors 8. Patients who have a congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU/ml), hepatitis C (positive for hepatitis C antibodies and HCV-RNA above the lower limit of detection of the assay) or combined hepatitis B and hepatitis C co-infection 9. Patients who have a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation 10. The presence of thrombosis-type diseases or using anticoagulant drugs 11. Patients with any serious or uncontrolled systemic disease that, in the opinion of the investigator, may increase the risk associated with participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | Up to approximately 2 years | ORR is proportion of subjects with complete response(CR) or partial response(PR), based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | Up to approximately 2 years | Progression-free survival (PFS) is defined as the time from the first dose of investigational products until documentation of PD (as per RECIST v1.1) or death due to any cause, whichever occurs first. |
| Overall survival (OS) | Up to approximately 2 years | Overall survival (OS) is defined as the time from the first dose of investigational products until death due to any cause. |
| Disease control rate (DCR) | Up to approximately 2 years | Disease control rate (DCR) is defined as the proportion of subjects achieving a best of response(BOR) of confirmed CR and PR and stable disease(SD) per RECIST v1.1. |
| Duration of response (DoR) | Up to approximately 2 years | Duration of response (DoR) is defined as the period from the first documentation of confirmed response (CR or PR) to the first documentation of progressive disease(PD) (as per RECIST v1.1) or death due to any cause, whichever occurs first. |
| Incidence and severity of adverse events(AEs) | Up to approximately 2 years | Incidence and severity of AEs is aim to evaluate the safety of AK104 alone or combination with chemotherapy. |
Other
| Measure | Time frame | Description |
|---|---|---|
| The expression of PD-L1 in tumor tissue | Up to approximately 2 years | The expression of PD-L1 is aim to investigate the relationship between PD-L1 and anti-tumor efficacy. |
| The level of ctDNA in blood | Up to approximately 2 years | The level of ctDNA is aim to investigate the relationship between ctDNA and anti-tumor efficacy. |
Contacts
Primary ContactYun Liu, M.D.
Outcome results
None listed